

HORMONE RELATED TUMORS

EDITED BY
HIROSHI NAGASAWA
KAORU ABE

JAPAN SCIENTIFIC SOCIETIES PRESS
Tokyo
SPRINGER-VERLAG
Berlin Heidelberg New York

HORMONE RELATED TUMORS

EDITED BY

HIROSHI NAGASAWA
KAORU ABE

JAPAN SCIENTIFIC SOCIETIES PRESS

Tokyo

SPRINGER-VERLAG

Berlin Heidelberg New York

1981

© JAPAN SCIENTIFIC SOCIETIES PRESS, 1981

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Supported in part by the Ministry of Education, Science and Culture under the Publication Grant-in-Aid.

Published jointly by
JAPAN SCIENTIFIC SOCIETIES PRESS Tokyo
ISBN 4-7622-0290-8

and

SPRINGER-VERLAG Berlin Heidelberg New York
ISBN 3-540-10925-0 SPRINGER-VERLAG Berlin Heidelberg New York
ISBN 0-387-10925-0 SPRINGER-VERLAG New York Heidelberg Berlin

Sole distribution rights outside Japan granted to SPRINGER-VERLAG Berlin Heidelberg New York

Printed in Japan

Preface

Marked progress has been achieved in these years in research on tumors of hormone target organs, to which recent developments in radioimmunoassay, radioreceptor assay, and immunohistochemical analysis of hormones have contributed a great deal. The importance of research on these tumors is increasing with the growing complexity of our social, mental, and daily lives. This is well reflected by several international symposia on hormones and cancers, most of the results of which are published as proceedings.

However, books which include in one volume original reviews of recent progress in both experimental and clinical research on hormone related tumors are scarce despite the great significance of this subject. This is the reason why we are publishing this book. Articles were prepared by the most active and leading investigators in the world. They include extensive survey and discussion from the endocrinological standpoint of updated publications on the development, progression, characteristics, biology, and theories of diagnosis and therapy of major hormone related tumors.

We believe this book will be of much benefit not only to experimental and clinical researchers in related fields, but also to students and physicians.

We gratefully acknowledge all the contributors who accepted our invitation. Our thanks are also due to the Ministry of Education, Science and Culture, Japan, for financial support.

Tokyo, May 1981

Hiroshi NAGASAWA Ph.D.
Kaoru ABE M.D.

Contributors

- Abe, K. Endocrinology Division, National Cancer Center Research Institute, Tokyo 104, Japan
- Baba, S. The Second Department of Internal Medicine, Kobe University School of Medicine, Kobe 650, Japan
- Dazord, A. Unité de Recherches sur le Contrôle Hormonal des Activités Cellulaires, INSERM U162, Hôpital Debrousse, 69322 Lyon, France
- Falkowski, W. Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611, U.S.A.
- Grayhack, J.T. Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611, U.S.A.
- Ito, A. Research Institute for Nuclear Medicine and Biology, Hiroshima University, Hiroshima 734, Japan
- Jesik, C. Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611, U.S.A.
- Kazumi, T. The Second Department of Internal Medicine, Kobe University School of Medicine, Kobe 650, Japan
- Kimura, J. Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto 602, Japan
- Lee, C. Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611, U.S.A.
- Mori, T. Zoological Institute, Faculty of Science, University of Tokyo, Tokyo 113, Japan

- Nagasawa, H. Pharmacology Division, National Cancer Center Research Institute, Tokyo 104, Japan
- Okada, H. Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto 602, Japan
- Pour, P.M. The Eppley Institute for Research in Cancer, University of Nebraska, Medical Center, Omaha, Nebraska 68105, U.S.A. and Sandoz AG, Preclinical Research, Department of Toxicology, CH-4133 Pratteln 4, Switzerland
- Robyn, C. Human Reproduction Research Unit, Université Libre de Bruxelles, Hôpital Saint-Pierre, 1000 Brussels, Belgium
- Saez, J.M. Unité de Recherches sur le Contrôle Hormonal des Activités Cellulaires, INSERM U162, Hôpital Debrousse, 69322 Lyon, France
- Takasugi, N. Department of Biology, Yokohama City University, Yokohama 236, Japan
- Tell, G.P.E. Centre de Recherche Merrell International, 60784 Strasbourg, France
- Teng, C.S. Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
- Uke, E. Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611, U.S.A.
- Vorherr, H. Departments of Obstetrics-Gynecology and of Pharmacology, The University of New Mexico, School of Medicine, Albuquerque, New Mexico 87131, U.S.A.
- Williams, E.D. Department of Pathology, Welsh National School of Medicine, Heath Park, Cardiff, Wales, Great Britain
- Yokoro, K. Research Institute for Nuclear Medicine and Biology, Hiroshima University, Hiroshima 734, Japan
- Yoshino, G. The Second Department of Internal Medicine, Kobe University School of Medicine, Kobe 650, Japan

Contents

Preface	v
Contributors	<i>xi</i>

PITUITARY TUMOR

Experimental Pituitary Tumors	K. Yokoro and A. Ito	3
I. Spontaneous pituitary tumors		4
II. Induction and pathogenesis of pituitary tumors		6
III. Transplantable pituitary tumors as a tool for studies of carcinogenesis		16
VI. Conclusion		17
Summary		17
Hormone Secreting Pituitary Tumors in Man: Prolactinomas, Acromegaly and Cushing's Disease	C. Robyn	23
I. Etiology		24
II. Clinical features		28
III. Treatment		40
Summary		43

ADRENAL TUMOR

Human and Experimental Adrenocortical Tumors	A. Dazord, G.P.E. Tell, and J.M. Saez	53
I. Clinical aspects of human adrenocortical tumors		54
II. Biochemical alterations of adrenocortical tumors		61
Summary		76

THYROID TUMOR

Endocrine Tumours of the Thyroid	E.D. Williams	87
I. Follicular tumours of the thyroid		88
II. C-cell tumours of the thyroid		93
III. Conclusions		95
Summary		96

PANCREATIC TUMOR

The Endocrine-Exocrine Pancreas: Its Clinical and Morphological Aspects and Hyperplastic and Neoplastic Patterns	P.M. Pour	103
I. Background		103
II. Hyperplasia and neoplasia of endocrine-exocrine pancreas		107
Summary		116
Insulinomas of the Rat Pancreas Induced by Streptozotocin	T. Kazumi, G. Yoshino, and S. Baba	121
I. Incidence		121
II. Chronology		124
III. Morphology		125
IV. Hormone content of tumors and hosts' pancreases		128
V. Insulin responses to glucose in tumor-bearing rats		129
Summary		132

MAMMARY TUMOR

Hormones and Experimental Mammary Tumorigenesis	H. Nagasawa	137
I. Prolactin (PRL)		137
II. Growth hormone (GH)		142
III. Estrogen		143
IV. Progesterone		147
V. Thyroid hormones		149
VI. Androgen		150
VII. Estrous cycles and reproduction in relation to mammary tumorigenesis		151
VIII. Effects of pregnancy and lactation on mammary tumorigenesis		152
IX. Inhibition of carcinogen-induced mammary tumorigenesis in rats by luteinizing hormone-releasing hormone (LH-RH)		153
X. Long-term effects of perinatal exposure to hormones and drugs on normal and neoplastic mammary growth		153

XI. Immune mechanism and mammary tumors	156
XII. Hormones and mammary tumor virus (MTV) production	156
Summary	157
Hormones and Prostaglandins in Relation to Breast Cancer H. Vorherr	165
I. Prolactin in relation to breast cancer	165
II. Growth hormone and insulin in relation to breast cancer	168
III. Melatonin in relation to breast cancer	169
IV. Thyroid hormone(s) in relation to breast cancer	169
V. Thymus in relation to breast cancer	172
VI. Glucocorticosteroids in relation to breast cancer	173
VII. Sex steroids in relation to breast cancer	176
VIII. Prostaglandins in relation to breast cancer	188
Summary	190

UTERINE TUMOR

Uterine Tumors and Hormone Dependency J. Kimura and H. Okada	201
I. Hormonal regulation of cell proliferation and differentiation in the endometrium	203
II. Effects of steroid hormones on cell division in endometrial hyperplasia and adenocarcinoma	207
III. Immunocytochemical and cytofluorometric evaluation of cellular heterogeneity of hormone dependency of endometrial carcinoma	211
IV. Potentially useful indicators for hormone dependency of endometrial adenocarcinoma	216
Summary	219

VAGINAL TUMOR

Cervico-Vaginal Tumors in Humans and Laboratory Animals	
T. Mori and N. Takasugi	227
I. Cervico-vaginal tumors in humans	228
II. Vaginal abnormalities related to prenatal exposure to diethylstilbestrol	232
III. Cervico-vaginal tumors in laboratory animals	234
IV. Cervico-vaginal tumors related to perinatal exposure to sex steroids	236
Summary	238

OVARIAN TUMOR

Natural Occurrence and Experimental Induction of Ovarian Tumors

C.S. Teng 243

- I. Characteristics and classification of ovarian tumors 244
- II. Progression of ovarian tumors 247
- III. Progress in ovarian tumor treatments 252
- Summary 255

PROSTATIC TUMOR

Prostatic Neoplasia: Clinical and Experimental

C. Lee, C. Jesik, E. Uke, W. Falkowski, and J.T. Grayhack 261

- I. Prostatic neoplasia: clinical 262
- II. Prostatic neoplasia: experimental 271
- Summary 280

TESTICULAR TUMOR

Testicular Neoplasia: Clinical and Experimental

C. Lee, C. Jesik, W. Falkowski, E. Uke, and J.T. Grayhack 289

- I. Background 290
- II. Risk factors 291
- III. Pathology 292
- IV. Tumor markers 294
- V. Diagnosis and staging 296
- VI. Treatment 298
- VII. Current status of experimental investigations in testicular
neoplasia 299
- VIII. Discussion 304
- Summary 305

Subject Index 313

1

PITUITARY TUMOR

Experimental Pituitary Tumors

KENJIRO YOKORO AND AKIHIRO ITO

*Research Institute for Nuclear Medicine and Biology,
Hiroshima University, Hiroshima 734, Japan*

It has been generally accepted that the anterior pituitary of mammals is made up of five distinct cell types from which ten different hormones are secreted. Although the development of tumors from the respective cell types is accepted theoretically, tumors derived from every cell type have not necessarily been observed, and the response of cells to tumorigenic stimuli is greatly dependent on both the cell type and the species. Experimental studies on pituitary tumors (PT) may contribute toward the exploration of endocrinological problems including the following aspects. i) Functional PT are the suitable models for the comparative study of pathophysiology in PT patients. ii) PT can be utilized as the source for determination of the molecular structure of a given hormone. iii) Induction of PT by deranging the homeostatic balance of the feedback mechanism without any carcinogenic treatment appears to be an excellent model for studying the mechanism of evolution from a hyperplastic to a neoplastic state cell. iv) A transplantable PT should be a good source for a continuous supply of an endogenous hormone in evaluating the role of pituitary hormones in the development and progression of tumors in various target tissues. Unlike other tissues, the pituitary has not been the primary target of any carcinogens except radiation, by which certain

types of PT have been induced probably as a part of its random tumorigenic effect. The PT genes appear to represent the uniqueness of the tumorigenic mechanism in the endocrine system. In this review, we will briefly describe the available data obtained through studies of experimental pituitary tumors, mainly in mice and rats (22, 31).

I. SPONTANEOUS PITUITARY TUMORS

Spontaneous PT have been observed in many species of mammals including humans. In old rats, the frequency of PT seems to be quite high if they are carefully observed. The development of PT is usually not common in rats less than 18 months old, but it increases with age.

A survey by Russfield (75) from old literature and our recent observations on the incidence of spontaneous PT in aged rats indicated that there is a great strain difference, ranging from 4 to 94% (Table I); *e.g.*, in Shermann rats only 4% in males (77) and 62% in females (52); in Wistar rats 12% in males and 68% in females (90); in Wistar/Furth (W/Fu) rats 60% in males (51) and 27% in females (53); and a 94% incidence was noted in male Long-Evans rats (38). Sass *et al.* (76) recently reported that PT developed in 35.9% of females and 23.8% of males of Fischer (F-344) rats kept throughout their natural lifespan.

Although there have been no standard rules for the diagnosis of PT in an individual report, a pituitary gland weighing more than 19 mg in rats and

TABLE I
Incidence of Spontaneous Pituitary Tumors in Rats

Strain	Male (%)	Female (%)	Observation period (months)	Ref.
Wistar	12	68	24	Wolfe <i>et al.</i> , 1938 (90)
Yale (Osborne-Mendel)	60	30	20	Saxton and Graham, 1944 (77)
Shermann	4	—	24	Saxton and Graham, 1944 (77)
W/Fu	—	27	>17	Kim <i>et al.</i> , 1960 (53)
R (Amsterdam)	—	60	>33	Kwa, 1961 (57)
Long-Evans	94	—	24	Griesbach, 1967 (38)
Shermann	—	62	>21	Kaunitz <i>et al.</i> , 1970 (52)
Charles River	48.8	—	>21	Ito <i>et al.</i> , 1972 (51)
W/Fu	60	—	>21	Ito <i>et al.</i> , 1972 (51)
F 344	24	36	>22	Sass <i>et al.</i> , 1975 (76)
ACI/N	6	21	42	Maekawa and Odashima, 1975 (62)

TABLE II
Incidence of Spontaneous Pituitary Tumors in Mice

Strain	Male (%)	Female (%)	Age (months)	Ref.
(O ₂₀ × DBAf)F ₁	—	10	Old	Mühlbock, 1951 (68)
(C57 × A)F ₁	—	8	36	Upton and Furth, 1955 (84)
A	0	—	28	Furth <i>et al.</i> , 1957 (19)
C57L	—	+	28	Furth <i>et al.</i> , 1957 (19)
NZY	—	25	>12	Bielschowsky <i>et al.</i> , 1956 (4)
C57BL/6J	0	75	30	Schechter <i>et al.</i> , 1979 (78)

3 mg in mice have been empirically scored as tumors, in which microtumorous foci can be found by histological examination (51). There appears to be no sex preference in the prevalence of spontaneous tumors. In general, the frequency of spontaneous development of PT in rats is higher than in mice. In this review, we will use the nomenclature for PT in conformity with that proposed by Furth *et al.* (22). Kim *et al.* (53) first described the functional characteristics of spontaneous PT by observing the physiological changes in primary tumor-bearers and by transplantation studies, and concluded that most, if not all, of the tumors are mammo-somatotropic. Kwa *et al.* (58) and Ito *et al.* (51) later confirmed this by using radioimmunoassay and immuno-histochemical staining. Immunocytological and fine structural studies of spontaneous PT have revealed the existence of prolactin cells in the tumors (56). In contrast with estrogen-induced PT which are usually fully hormone dependent in the early transplantation passages, spontaneous PT are autonomous even in the original passage (51, 53).

The pathogenesis of spontaneous PT has been little known. It is supposed that various estrogenic stimuli in females and an increased secretion of estrogen by conversion of androgen to estrogen in aged males are responsible for the high frequency of spontaneous PT in rats.

Spontaneous PT in mice have been extensively reviewed by Kwa (57) and Liebelt (59). The frequency of spontaneous PT in various mouse strains is tabulated in Table II. An exceptionally high incidence (75%) was reported in female C57BL/6J mice, but the incidence is nil in males (78).

In contrast with rat tumors, information on the functional characteristics of spontaneous PT in mice is rather scanty. The majority of tumors in mice have been described histologically as chromophobic, but many are now considered to be functionally mammatropic.

II. INDUCTION AND PATHOGENESIS OF PITUITARY TUMORS

In 1936, several groups of investigators first announced the successful induction of PT in mice and rats by prolonged administration of estrogens (5, 11, 34, 63, 65, 72, 97). These reports were then followed by the induction of PT in rodents by various other means such as exposing the animals to whole-body or partial-body X-irradiation (26, 83, 86, 93), abrogating the thyroidal function (3, 12, 13, 15, 16, 36, 67, 94), and ectopic grafting of pituitary glands (33, 43, 60, 69).

It has been claimed by some investigators that neonatal gonadectomy is also effective in inducing PT, but the reproducibility has been rather poor. Valid procedures for induction of PT in mice and rats are listed in Table III.

The majority of PT induced by these procedures are functional and capable of hormone production. PT thus induced have been classified basically into the following four types according to the qualities of hormones produced (22). i) Mammatropic tumor (MtT) that secretes mammatropic hormone (MtH, prolactin); the functional activity of MtT is often accompanied by somatotropic and sometimes also by adrenocorticotropic activities. ii) Thyrotropic tumor (TtT) that secretes thyrotropic hormone (TtH). iii) Adreno-

TABLE III
Experimental Induction of Functional Pituitary Tumors in Mice and Rats

Tumor type and principal hormone	Variant and accompanying effect	Inducing agent or procedure	Species
MtT Prolactin	MStT	a) Estrogen	a) Mouse, rat
	StH	b) Radiation	b) Mouse, rat
	MSAtT StH+ACTH	c) Pituitary isograft	c) Mouse, rat
TtT TtH (TSH)	GtT	a) Radiothyroidectomy (^{131}I)	a) Mouse
	GtH	b) Surgical thyroidectomy	b) Mouse
		c) Propylthiouracil	c) Mouse
		d) ^{131}I +X-rays	d) Rat
AtT ACTH		Radiation	Mouse
GtT GtH		Gonadectomy?	Rat

tropic tumor (AtT) that secretes adrenocorticotrophic hormone (ACTH). iv) Gonadotropic tumor (GtT) that secretes gonadotropic hormone (GtH).

The growth of PT induced by administration of estrogen or by derangement of the hormonal balance are usually dependent on or responsive to the hormones involved, while that of PT induced by radiation or developing spontaneously are autonomous (hormone independent); they grow equally regardless of the hormonal status of the host (23, 93).

1. Mammotropic Tumor (MtT) and the Variants

MtT is a tumorous growth of acidophils of the anterior pituitary. The majority of spontaneously developing PT in rodents are of this type, as described in the previous section, and can readily be induced by various means in mice and rats (22, 31). MtT is a morphologically chromophobic or acidophilic adenomas. Since tumor-bearing animals show a proliferation of the mammary gland with milk secretion, these tumors were initially designated as MtT. Later, it was demonstrated, by hormone assay and secondary changes in tumor-bearers, especially in animals bearing transplanted MtT, that many of these types of tumors also secrete somatotrophic hormone (StH) and, occasionally, also adrenotropic hormone (AtH) concomitantly with prolactin. Thus, it is logical to call them mammo-somatotropic tumors (MStT) or mammo-somato-adrenotropic tumors (MSAtT). In MtT-bearing males, the somatotrophic effect is more prominent as compared with that in females in which the prolactin effects are conspicuous.

1) MtT induction

a) Administration of estrogens MtT can readily be induced in mice and rats with a high frequency by prolonged administration of natural estrogens such as estrone, estradiol, and estriol, and of synthesized estrogen, diethylstilbestrol (DES). Strain differences in susceptibility to estrogen-induced PT genesis in mice has been reported. MtT could be induced in about 50% of young female (C57L × A/He)F₁ mice with a latency of 45–100 weeks, by administering a cholesterol pellet containing 0.05–0.1 mg of DES, renewed at a 3-month interval starting at 8–10 weeks of age (93).

In rats, MtT can be induced with higher frequency than in mice. It was observed in our laboratory that chronic administration of a cholesterol pellet containing 5 mg of DES results in the development of MtT in 100% of female ACI/N rats and about 80% of Sprague-Dawley and W/Fu rats within 50 weeks. The induction of MtT at a high rate in female Fischer (F-344) rats by a similar DES treatment has also been reported (23).

b) Isografts of pituitary gland Mühlbock and Boot (69) first introduced the